Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

IBRX

ImmunityBio (IBRX)

ImmunityBio Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IBRX
DateTimeSourceHeadlineSymbolCompany
14/06/202408:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
14/06/202408:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
14/06/202408:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
14/06/202408:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
14/06/202408:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
14/06/202408:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
13/06/202406:36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IBRXImmunityBio Inc
07/06/202423:13Business WireImmunityBio Announces 2024 Annual Meeting of Stockholders with Company UpdateNASDAQ:IBRXImmunityBio Inc
17/05/202423:00Business WireConnecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday PodcastNASDAQ:IBRXImmunityBio Inc
10/05/202407:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IBRXImmunityBio Inc
07/05/202422:00Business WireImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®NASDAQ:IBRXImmunityBio Inc
03/05/202406:04Business WireImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer TypesNASDAQ:IBRXImmunityBio Inc
30/04/202422:00Business WireImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological AssociationNASDAQ:IBRXImmunityBio Inc
25/04/202414:03Business WireImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung CancerNASDAQ:IBRXImmunityBio Inc
23/04/202411:56Business WireImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder CancerNASDAQ:IBRXImmunityBio Inc
07/03/202401:00Business WireNIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral TherapyNASDAQ:IBRXImmunityBio Inc
06/03/202401:00Business WireN-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure StudyNASDAQ:IBRXImmunityBio Inc
27/02/202408:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
27/02/202408:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
27/02/202408:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
24/02/202413:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IBRXImmunityBio Inc
22/02/202401:00Business WireImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the TrialNASDAQ:IBRXImmunityBio Inc
07/02/202413:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
06/02/202401:00Business WireImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCGNASDAQ:IBRXImmunityBio Inc
03/02/202411:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
03/02/202411:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
04/01/202413:59Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:IBRXImmunityBio Inc
04/01/202413:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
04/01/202413:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
02/01/202422:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IBRXImmunityBio Inc
 Showing the most relevant articles for your search:NASDAQ:IBRX